Exponential Technology Report 2026: Synthetic Biology and Bioengineering

S.1Abstract

S.2Key messages

Six readings that frame the synthetic biology baseline, and the eight questions this edition answers, each with its status and source.

1. A bacterium with a 57-codon code and a yeast strain with six and a half synthetic chromosomes.²⁴

   How far has genome writing come?Reported

2. Yes at the scale of tens of circuits and designed binders, in peer-reviewed tests.⁶⁷

   Can circuits and proteins be designed by software?Reported

3. A CRISPR therapy was authorised in the US in December 2023.⁸⁹

   Do engineered therapies reach patients?Reported

4. A 2025 study found tools often missed redesigned sequences; patches helped.¹³

   Is DNA screening keeping up with design tools?Reported

5. A US commission report, an EU proposal, OECD and CBD work; uneven implementation.¹⁴¹⁸²²

   What does governance look like?Reported

6. Company results are mixed: Ginkgo revenue fell in 2025, Twist raised its 2026 guidance.¹⁶¹⁷

   What does the money look like?Reported

7. Not published on a common basis; no figure bound.²⁴

   What is the physical footprint?Expert input

8. Whether screening and governance keep pace with design and cheap DNA. SCN-XT04-DSG-01

   What will 2027 test first?Expert input

S.3Headline finding

ReportedEQL 4NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001

A bacterium with a 57-codon genetic code was reported in Science in 2025, seven codons fewer than the standard 64, with over 101,000 codon changes in a synthetic genome of about 4 million base pairs.

Whole-genome design and writing now works at the scale of a bacterial genome. The authors state aims such as further compression and tests of viral resistance; those are plans, not results¹². The result shows capability on one organism and says nothing about industrial use, cost or safety in the field.

S.4At a glance

S.5What each steward reads in it

S.6What this edition is, and is not

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
2. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back
3. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
4. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
5. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
6. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
7. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
8. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
9. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
10. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
11. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
12. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
13. 9US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
14. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
15. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back

1.1The questions this part answers

Key questions

• Where is synthetic biology risk concentrated?
• Which couplings carry synthetic biology shocks into other systems?
• Which synthetic biology capabilities hold under compound stress?
• What must 2027 evidence measure first?

In this part

• Narrative
• Headline finding
• Lead figure
• Five footprint and governance chapters
• Twelve-domain reading
• Sector screens
• Dependency matrix
• Risk objects
• Capability ladder
• Scenario
• Three lenses
• Portfolio

1.2The argument

1.3Twenty couplings between five systems

The synthetic biology-centred matrix types the twenty couplings between the five core systems, read for their synthetic biology content. Strengths are Nexus estimates (ESTIMATED) from the cited evidence and analogue events; they set the graph that 2027 evidence will test.

Transmission paths

1. 01

   DAT → BIO → SEC

   Design tools and sequence data lower the barrier to misuse faster than screening adapts.

   Reported 2025 screening study¹³

2. 02

   BIO → HLT

   Engineered cell therapies move from research to patients.

   Reported exa-cel trial and regulator announcement⁸⁹

3. 03

   FIN → INF

   Public programmes fund manufacturing planning.

   Reported US programme awards²³²⁴

4. 04

   ENE → BIO

   Process energy and feedstock constrain manufacturing at scale.

   Inferred no figure bound

5. 05

   GOV → BIO

   Frameworks and proposals set oversight and incentives.

   Reported US, EU and OECD documents¹⁴¹⁸²²

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
2. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
3. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
4. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back
5. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
6. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
7. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
8. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
9. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
10. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
11. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
12. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
13. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
14. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
15. 9US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
16. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
17. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back

2.1Headline finding

ReportedEQL 4NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001

A bacterium with a 57-codon genetic code was reported in Science in 2025, seven codons fewer than the standard 64, with over 101,000 codon changes in a synthetic genome of about 4 million base pairs.

Implication

Whole-genome design and writing now works at the scale of a bacterial genome. The authors state aims such as further compression and tests of viral resistance; those are plans, not results¹². The result shows capability on one organism and says nothing about industrial use, cost or safety in the field.

What would move it

Peer-reviewed tests of viral resistance, independent replication and any published cost of whole-genome synthesis would each move this finding.

2.2BLD

1. ReportedEQL 4NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001

   A bacterium with a 57-codon genetic code was reported in 2025. Its synthetic genome of about 4 million base pairs carries over 101,000 codon changes and was built from 38 fragments of about 100,000 base pairs; an earlier strain recoded 18,214 codons and uses 61 codons.¹²³⁴⁴

2. ReportedEQL 4NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-002

   By 2023 a single yeast strain carried six and a half synthetic chromosomes, over half of the synthetic yeast genome design; in 2010 the first cell run by a chemically synthesised genome had a 1.08 million base pair genome.⁴⁵⁴³

3. ReportedEQL 4NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-003

   A 2016 design automation tool built 60 genetic circuits in E. coli, 45 worked in every output state and 92% of output states matched predictions; a 2023 generative method designed protein binders, and one binder to influenza hemagglutinin matched its design model in a cryo-EM structure.⁶⁷

2.3CLN

1. ReportedEQL 4NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-CLN-004

   A CRISPR-edited cell therapy was authorised by the US regulator on 8 December 2023; in a phase 3 study 29 of 30 evaluable patients (97%) were free of severe crises for 12 months, and in 2025 a patient-specific base-editing therapy was given to one infant.⁸⁹¹⁰

2.4Security

1. ReportedEQL 4NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SEC-005

   A 2025 Science study found that current screening tools often failed to detect sequences redesigned with open machine-learning protein design software, and reported patches that substantially improved detection.¹³

2. ReportedEQL 3NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SEC-006

   A 2024 Science policy forum on mirror life called for broad discussion on a path forward.¹²

2.5Governance

1. ReportedEQL 2NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-007

   Executive Order 14292 of May 2025 gave OSTP 90 days to revise or replace the 2024 US framework for nucleic acid synthesis screening; a Congressional Research Service note found in July 2026 that it could not determine whether either had been revised, and sources differ on whether the framework is in force.^25262730

2. ReportedEQL 3NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-008

   The US National Security Commission on Emerging Biotechnology delivered its final report on 8 April 2025 with 49 recommendations and a call for at least USD 15 billion over five years.¹⁴¹⁵

3. ReportedEQL 2NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-009

   The European Commission proposed a Biotech Act on 16 December 2025, centred on health biotechnology, with an investment pilot with the European Investment Bank Group, a 12-month certificate extension and biodefence measures; a second act on the wider ecosystem was expected in the third quarter of 2026.²²²⁸²⁹

4. ReportedEQL 3NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-010

   The OECD found in May 2026 that governments are moving toward adaptive synthetic biology governance but that implementation remains uneven; the CBD asked in decision 16/21 for a thematic action plan on capacity building and technology transfer.¹⁸¹⁹²⁰

2.6Finance

1. ReportedEQL 2NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-FIN-011

   Ginkgo Bioworks reported revenue of USD 170.2 million for 2025 against USD 227.0 million for 2024, and Twist Bioscience reported USD 332.8 million for the nine months to 30 June 2026 with full-year guidance of USD 456 to 457 million. These are company statements.¹⁶¹⁷

2.7Systemic

1. Expert inputEQL 2NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SYS-012

   The leading compound pathway for 2027 testing is design capability and cheap DNA moving faster than screening practice and governance, while the footprint of the manufacturing base stays unmeasured. § scenario

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back
2. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
3. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
4. 44UNVERIFIED, not opened: bioRxiv preprint of the Syn57 study, Escherichia coli with a 57-codon genetic code, 2025, identified from a search result; the page returned HTTP 429. Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03.back
5. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
6. 5Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03.back
7. 43UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03.back
8. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
9. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
10. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
11. 9US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
12. 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
13. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
14. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
15. 25UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.back
16. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
17. 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back
18. 30UNVERIFIED, not opened: Engineering Biology Research Consortium (ed.), response on nucleic acid synthesis screening under Executive Order 14292, November 2025, listed in search results only. EBRC, Emeryville. Observation year 2025. Accessed 2026-11-03.back
19. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
20. 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.back
21. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
22. 28UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.back
23. 29UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03.back
24. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
25. 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.back
26. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
27. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
28. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back

3.1Where each system stood at evidence close

3.2Domain posture

Each of the twelve coupled domains is read through synthetic biology, in words, not scored. The coupling column names the dependency that carries synthetic biology risk into each domain.

3.3Sector screens

All sixteen sectors are screened for their dependence on synthetic biology, on the same grammar as every national edition. The evidence column describes coverage of the baseline evidence, not the performance of the sector.

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
2. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back
3. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
4. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
5. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
6. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
7. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
8. 9US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
9. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
10. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
11. 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.back
12. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
13. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
14. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
15. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
16. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
17. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
18. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back

4.1Risk objects

Each risk is read across the chain from hazard to consequence, with its status and evidence-quality level.

1. InferredEQL 3RSK-XT04-SEC-001

   Design capability outpaces screening

   Driver

   open machine-learning design tools and low-cost DNA⁷¹³

   Exposure

   sequence-handling and synthesis providers

   Vulnerability

   uneven screening practice; benchtop and small providers

   Capacity

   screening guidance, patches and oversight frameworks^13253132

   Cascade

   DAT → BIO → HLT

   Horizon

   1 to 5 years

2. InferredEQL 3RSK-XT04-GOV-002

   Fragmented and shifting oversight

   Driver

   unclear status of the US framework; separate EU and CBD tracks^20222627

   Exposure

   research collaboration; cross-border orders

   Vulnerability

   uneven implementation across jurisdictions¹⁸

   Capacity

   OECD and WHO guidance; national strategies¹⁸²¹

   Cascade

   GOV → BIO, FIN

   Horizon

   1 to 5 years

3. Expert inputEQL 2RSK-XT04-SUP-003

   Manufacturing base thinner than headlines

   Driver

   mixed company results and planning-stage public awards¹⁶¹⁷²⁴

   Exposure

   products that depend on scale-up

   Vulnerability

   few counted facilities; unmeasured feedstock needs

   Capacity

   institute and awards programme²³²⁴

   Cascade

   FIN → INF → BIO

   Horizon

   1 to 10 years

4. InferredEQL 2RSK-XT04-ENV-004

   Release and novel-organism questions

   Driver

   gene drives and organisms with altered codes or chirality¹¹¹¹²

   Exposure

   ecosystems; public trust

   Vulnerability

   limited field evidence; international rules still forming

   Capacity

   CBD process and protocol²⁰³⁵

   Cascade

   BIO → BIO biodiversity systems

   Horizon

   5 to 10 years

4.2Capability ladder

Existence is not readiness. Each of the fifteen capability functions is placed on the ladder by the strongest public evidence for synthetic biology at the global level.

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
2. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
3. 25UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.back
4. 31UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03.back
5. 32UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03.back
6. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
7. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
8. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
9. 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back
10. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
11. 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.back
12. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
13. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
14. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
15. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
16. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
17. 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.back
18. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
19. 35UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03.back
20. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
21. 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.back
22. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
23. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back

5.1Assumptions

Scenario SCN-XT04-DSG-01: what is assumed, and what is held constant.

Baseline

the 2026 reference state in this edition

Drivers

design tools and low-cost DNA improve faster than screening practice and framework text

Analogues

the 2025 screening study and the 2025 executive order¹³²⁶

Interventions

none modelled: the specification describes the unmitigated case

Run state

narrative specification; quantified run scheduled for 2027

5.2The cascade, step by step

1. 1

   AIC → BIO

   design tools make novel sequences easier to produce

   2023

2. 2

   DAT → SEC

   screening tools miss some redesigned sequences

   2025

3. 3

   GOV → SEC

   framework text is revised while practice differs by provider

   2025

4. 4

   FIN → INF

   investment concentrates in providers with in-house screening

   2026

5. 5

   GOV → TRD

   national rules and export controls diverge

   2026

6. 6

   BIO → HLT

   public trust in engineered products is tested

   2025

5.3The scenario as a table of steps

How the shock in scenario SCN-XT04-DSG-01 would travel through Synthetic Biology and Bioengineering’s coupled systems, step by step, under the assumptions the edition states.

A teaching model of a conditional scenario under the edition’s stated assumptions: not a forecast, not a prediction and not a warning. Sources: Synthetic Biology and Bioengineering 2026, scenario SCN-XT04-DSG-01 (2026); Synthetic Biology and Bioengineering 2026, references (NR-CIT-1) (2026).

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
2. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back

6.1The other desks’ editions of this subject

Federation: each desk writes its own edition for the subjects in its remit. Until a desk releases, its edition shows its frame and the reading this edition printed for it.

6.2Three lenses

One edition, read by each steward. The lens of this site comes first.

6.3Standards, Academy and steward contributions

How the Nexus Standards drafts, the Risk Academy and the three stewards feed each quarterly edition for synthetic biology. The standards are a preparatory working draft (2026) and are cited as drafts, never as adopted standards.

6.4GCRI reading: the model card

GCRI’s reading of this edition is its model card: what the national model is, what it computes and where it stops. It is printed in full in Annex A, with the methods it belongs to. Annex A, methodology

6.5Global Risks Forum reading: editorial essays

Four signed essays by the Reports editorial team set out the positions this edition takes. They are interpretation, labelled as such; the evidence they draw on is in the findings register.

6.6Global Risks Alliance reading: 2027 synthetic biology readiness pack

The registers that open the 2027 global cycle. At baseline each is initialised from this edition.

Publication dispositions

• Publish
• Hold
• Needs evidence
• Restricted
• Superseded

6.7Nexus Standards reading: standards and regulatory watch

Instruments and published guidance that shape the systems in this edition, by status on the retrieval date. The edition assesses no one’s compliance.

• IN FORCE
• PUBLISHED
• DRAFT
• PUBLISHED · VOLUNTARY

6.8Risk Academy reading: literature and evidence review, science and assessments

The review behind this edition covers synthetic biology assessments, peer-reviewed science and the institutional reports that bind its findings. Systematic reviews for each agenda item begin in 2027.

Review protocol

Question

What does the published evidence establish about synthetic biology and bioengineering as infrastructure and its couplings?

Sources searched

peer-reviewed journals; regulator and agency pages; policy papers; company filings

Window

releases available at evidence close, 30 September 2026

Selection

sources that bind or contextualise a finding in this edition

Next step

systematic reviews for agenda items 01 to 05 in 2027

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
2. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
3. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
4. 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.back
5. 25UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.back
6. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
7. 31UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03.back
8. 32UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03.back
9. 36UNVERIFIED, not opened: International Organization for Standardization (ed.), ISO 20688-2, requirements for the production and quality control of synthesised gene fragments, genes and genome-scale constructs, cited from memory. ISO, Geneva. Observation year 2024. Accessed 2026-11-03.back
10. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
11. 28UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.back
12. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
13. 35UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03.back
14. 34UNVERIFIED, not opened: Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction, 1972, cited from memory. United Nations, Geneva. Observation year 1972. Accessed 2026-11-03.back
15. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
16. 29UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03.back
17. 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back
18. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
19. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
20. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
21. 5Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03.back
22. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
23. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
24. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
25. 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
26. 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.back
27. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
28. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
29. 38UNVERIFIED, not opened: Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 337, 816 to 821, 2012, cited from memory. Observation year 2012. Accessed 2026-11-03.back
30. 39UNVERIFIED, not opened: Gibson, D.G. et al., Enzymatic assembly of DNA molecules up to several hundred kilobases, Nature Methods 6, 343 to 345, 2009, cited from memory. Observation year 2009. Accessed 2026-11-03.back
31. 40UNVERIFIED, not opened: Ro, D.-K. et al., Production of the antimalarial drug precursor artemisinic acid in engineered yeast, Nature 440, 940 to 943, 2006, cited from memory. Observation year 2006. Accessed 2026-11-03.back
32. 41UNVERIFIED, not opened: Elowitz, M.B. and Leibler, S., A synthetic oscillatory network of transcriptional regulators, Nature 403, 335 to 338, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03.back
33. 42UNVERIFIED, not opened: Gardner, T.S., Cantor, C.R. and Collins, J.J., Construction of a genetic toggle switch in Escherichia coli, Nature 403, 339 to 342, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03.back
34. 43UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03.back
35. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
36. 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.back
37. 33UNVERIFIED, not opened: National Academies of Sciences, Engineering, and Medicine (eds.), Biodefense in the Age of Synthetic Biology, 2018, cited from memory; a fetch returned an unrelated page. National Academies Press, Washington. Observation year 2018. Accessed 2026-11-03.back
38. 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.back
39. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
40. 37UNVERIFIED, not opened: McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020, cited from memory; the fetch returned a service error and no figure is used. McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-03.back

7.1Questions for the operational series

1. Q-01

   How well do synthesis providers screen orders, and how do practices differ by country?

   INI-XT04-SCR-01 · screening coverage; first output: screening practice register.

2. Q-02

   What do fermentation and cell-free manufacturing need in energy, water and feedstock at commercial scale?

   INI-XT04-ENE-02 · manufacturing footprint; first output: footprint estimates by process.

3. Q-03

   Which DNA synthesis, instrument and reagent steps are single points of failure?

   INI-XT04-SUP-03 · DNA supply chain; first output: dependence map.

4. Q-04

   How much biofoundry and bioindustrial capacity exists, and where?

   INI-XT04-CAP-04 · manufacturing capacity; first output: capacity table.

5. Q-05

   How can public and private investment in synthetic biology be counted on one basis?

   INI-XT04-FIN-05 · investment on a common basis; first output: investment table.

6. Q-06

   Which national frameworks set screening or oversight rules, and how do they differ?

   To be admitted in 2027; first output: framework overlay.

7. Q-07

   What workforce exists for design, biofoundry operation and biosafety oversight?

   To be admitted in 2027; first output: scoping note.

8. Q-08

   Which readiness capabilities have been tested in real incidents, and which are only planned?

   Readiness capability register; first output: rung evidence for 15 functions.

7.2Portfolio proposed for the Q1 2027 alignment

Five initiatives and one Universe mission candidate are proposed for the 2027 synthetic biology portfolio. They are programme objects: no partner, funder or member is attached to them in this edition.

7.3The pathway

The synthetic biology edition reads national readiness chapters, the coupled sector reports on health, food and biosecurity, and the global edition through one governed evidence graph. At baseline the federation is designed; the global energy, health and food editions are drafted. This page states what exists today and what comes next.

1. 01

   National readiness chapters

   biotechnology and biosecurity readiness in each national edition

   IN PREPARATION · national baselines

2. 02

   Sector couplings

   GS-03 food · GS-04 health · XT-05 genomics · SR-08 biosecurity

   GS-04 DRAFTED · sector baselines

3. 03

   Technology system model

   platforms, DNA supply, manufacturing, workforce, governance

   v0 SPECIFIED · v1 with federation evidence

4. 04

   Strategic links

   SR-08 health security · SR-13 strategic technology

   PLANNED · strategic baselines

5. 05

   Universe

   annual proving environment

   CANDIDATE MISSION · mandate in 2027

6. 06

   XT-04 report

   this series

   BASELINE DRAFT · 2027 annual edition

7. 07

   Evidence and correction

   one graph, many projections

   OPEN · first correction cycle in 2027

7.4Universe 2027: evidence pack for the synthetic biology candidate mission

1. 01

   Mandate

2. 02

   Core Build · 1 month

3. 03

   Action · 1 week

4. 04

   Evidence seal

5. 05

   Portfolio correction

6. 06

   Next mandate

Mission

ID

MSN-XT04-2027-01 · Design and screening Universe mission

Role spine

Leadership sponsor · Institutional anchor · Mission lead: drawn from national pathways

Receiving actors

to be identified with the mandate

7.5Handoffs and routing

Where the baseline’s findings go next. A handoff routes a finding for awareness, review or work; it transfers no authority.

7.6Feeds and signal register

Escalation routes

• none · keep monitoring
• research question
• project
• risk object
• annual publication
• signal report

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
2. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
3. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
4. 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back

8.1Genome, circuit and protein design platforms

Biological design now spans whole genomes, genetic circuits and designed proteins. Evidence is strongest where peer review exists and weakest for industrial performance.

Related editions

• GLB Global Systems
• GS-04 Health and One Health
• GS-03 Food and Agrifood Systems
• XT-05 Genomics and Gene Editing
• SR-08 Health Security, One Health and Biosecurity
• XT-01 Artificial Intelligence and Agentic Systems

8.2Energy, water and feedstock for biomanufacturing

Fermentation and cell-free production need energy, process water and sugar or other feedstock. No source read counts them on a common basis.

Related editions

• GLB Global Systems
• GS-04 Health and One Health
• GS-03 Food and Agrifood Systems
• XT-05 Genomics and Gene Editing
• SR-08 Health Security, One Health and Biosecurity
• XT-01 Artificial Intelligence and Agentic Systems

8.3DNA, instruments and manufacturing capacity

The build base starts with synthesised DNA, instruments and reagents and ends in pilot and commercial plants. Public sources count programmes more than capacity.

Related editions

• GLB Global Systems
• GS-04 Health and One Health
• GS-03 Food and Agrifood Systems
• XT-05 Genomics and Gene Editing
• SR-08 Health Security, One Health and Biosecurity
• XT-01 Artificial Intelligence and Agentic Systems

8.4Economy, investment and workforce

Company results are mixed and the sector has no common investment series. Workforce numbers are the thinnest part of the evidence.

Related editions

• GLB Global Systems
• GS-04 Health and One Health
• GS-03 Food and Agrifood Systems
• XT-05 Genomics and Gene Editing
• SR-08 Health Security, One Health and Biosecurity
• XT-01 Artificial Intelligence and Agentic Systems

8.5Biosecurity and governance watch

The nearest governance test is whether screening and oversight keep pace with design tools. Frameworks exist, and their status and implementation differ by jurisdiction.

Related editions

• GLB Global Systems
• GS-04 Health and One Health
• GS-03 Food and Agrifood Systems
• XT-05 Genomics and Gene Editing
• SR-08 Health Security, One Health and Biosecurity
• XT-01 Artificial Intelligence and Agentic Systems

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back
2. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
3. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
4. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
5. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
6. 43UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03.back
7. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.back
8. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
9. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
10. 37UNVERIFIED, not opened: McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020, cited from memory; the fetch returned a service error and no figure is used. McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-03.back
11. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
12. 36UNVERIFIED, not opened: International Organization for Standardization (ed.), ISO 20688-2, requirements for the production and quality control of synthesised gene fragments, genes and genome-scale constructs, cited from memory. ISO, Geneva. Observation year 2024. Accessed 2026-11-03.back
13. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
14. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
15. 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.back
16. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
17. 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.back
18. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
19. 25UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.back
20. 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back
21. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
22. 28UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.back
23. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
24. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.back
25. 35UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03.back

A.1Methods

The global baseline uses published values and four simple derivations. Each is shown in full so that any reader can reproduce it.

A.2Model card, Synthetic biology System Model v0

Model ID

MDL-XT04-SYNBIO · v0.1

Purpose

represent synthetic biology as a build capability and manufacturing base coupled to health, food, energy, feedstock, finance, workforce and biosecurity

Family

graph-based system of systems

Inputs

the cited sources of this edition; no proprietary data

Method

expert-specified coupling strengths (STRONG · MODERATE · WEAK) from assessments and analogue events

Validation

none yet, first validation against federation evidence in 2027

Uncertainty

qualitative; strengths are hypotheses, not measurements

Domain of validity

global scale; not for asset-, site- or country-level use

Reproducibility

strength table and sources published in this edition

A.3The baseline evidence cut

Every Nexus edition is published from a frozen evidence cut. The global baseline cut is documentary: it pins the exact edition of every source cited. Federation cuts begin with the first national Foundry cuts in 2027.

Cut ID

DC-XTECH-SYNBIO-GLOBAL-2026-B0

Type

baseline documentary cut

Resolution policy

pinned · as of 30 September 2026

Sources pinned

44 cited sources, each at the edition and access date in the references

Model runs

none at baseline, analytical values are stated with their method

Digest

computed at freeze and recorded in the publication record

Supersedes

nothing, first cut of the series

Superseded by

the 2027 synthetic biology annual cut

Lineage

1. 01

   source edition

2. 02

   pinned citation

3. 03

   finding

4. 04

   page

5. 05

   publication record

A.4Evidence age and coverage

A 2026 global edition rests on evidence observed in many different years. This page shows each time base, so that no single year label hides older evidence.

A.5Evidence cards, two anchor sources

Evidence cards to follow in 2027

• Robertson et al.¹: viral resistance and replication
• Science screening study¹³: follow-up on patches and coverage
• US framework²⁵: replacement text
• European Commission²⁸: proposal text

A.6Publication acceptance record

Editorial self-check at evidence close. Every applicable item carries a disposition; the remaining items are review, approval and deposit.

A.7Status words

A.8How the edition is made, released and corrected

Every edition is built from a sealed evidence cut, reviewed under three keys, signed and deposited before any site shows it as published; corrections go to Nexus Standards as change proposals and feed the next cut.

A teaching model of the process, not a forecast and not a record of any run; dates and counts on this page come from the programme record. Sources: Reports governance at GCRI Canada (2026); Zenodo, repository of record for Reports deposits (2026).

Lifecycle, one state at a time: Draft, Computed, Evidence bound, Reviewed, Approved for release, Published, Corrected, Superseded. This edition is a draft.

A.9Glossary and abbreviations

A.10Technical annex

A.1 · indicator definition: codons recoded

Construct

number of codon positions in a genome replaced by a synonymous codon

Unit

count of codons

Method

genome design, fragment synthesis and assembly

Source

Nature 569 (2019)³; Science 390 (2025) and the research institute news page²

Uncertainty

the Syn57 count is stated as over 101,000, a lower bound

Known limits

counts may include sense codons and a stop codon; one lineage of organisms

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 25UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.back
2. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
3. 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.back
4. 28UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.back
5. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
6. 29UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03.back
7. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
8. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
9. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
10. 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.back
11. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
12. 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
13. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
14. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
15. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
16. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
17. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back

B.1The indicator set

B.2Global source register

The governed source set behind this edition. Each source keeps its authority, coverage, cadence and role; categories describe origin, not truth.

Domains bound by the register

• BLD
• SEC
• GOV
• FIN
• CLN
• ENE
• WAT
• FOO
• CLI
• MIN

B.3Regional reading, synthetic biology across ten clusters

Regional plates follow with the regional editions. This page gives the regional reading of synthetic biology infrastructure and governance in table form and ranks no region.

B.4Cluster card: DNA synthesis and screening chain

• supply chain
• DNA synthesis
• screening
• oversight

Systems in view

synthesis providers, design tools, sequence data, oversight bodies

Defining events

the 2025 screening study and the 2025 US executive order¹³²⁶

Couplings

DAT → BIO sequence data; GOV → SEC frameworks

Capability evidence

industry and national guidance exists³¹³²

Gaps

coverage by provider; benchtop devices; compliance

Agenda items

Q-01 · Q-03

B.5How countries appear in the synthetic biology edition

Countries enter the synthetic biology edition through the readiness chapters of their own national editions, on one card grammar. They are read against peer distributions and thresholds, never ranked.

Editions in the 2026 Baseline programme

How to read a country card

• Each system is shown against the distribution of its peers, with thresholds where they exist
• Couplings and risk objects come from the country’s own national edition
• Capability rungs record evidence, not a judgement of institutions
• Evidence age is printed, so older national data are visible as such

B.6Licences

B.7Formats and provenance

Provenance

Edition pack

The edition’s content pack (JSON), from which the print and web editions are built

Evidence cut

DC-XTECH-SYNBIO-GLOBAL-2026-B0, closed 30 September 2026

Reproducibility

sourced values cited; analytical values reproducible from stated parameters

Self-check

14 of 23 at evidence close; a fail on any item blocks release

Review

five passes scheduled before release (in Annex C)

Publisher of record

GCRI for the Nexus Consortium

Corrections

Registry correction pathway; upheld corrections are published as notices with a new version

Notes

Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references

1. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back
2. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
3. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.back
4. 5Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03.back
5. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.back
6. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
7. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.back
8. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
9. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
10. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
11. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.back
12. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
13. 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
14. 9US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.back
15. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
16. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.back
17. 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.back
18. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
19. 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.back
20. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.back
21. 31UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03.back
22. 32UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03.back

C.144 sources

NR-CIT-1, editor first. A DOI is linked where the source has one; Nexus records carry a UNI once the catalogue allocates it (NS-1).

1. 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 7, chapter 8
2. 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 8
3. 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 8
4. 4Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
5. 5Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03. Cited in chapter 2, chapter 6
6. 6Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
7. 7Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
8. 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6
9. 9US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3
10. 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2, chapter 6
11. 11Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03. Cited in chapter 3, chapter 4, chapter 6
12. 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 4, chapter 6
13. 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 5, chapter 6, chapter 7, chapter 8
14. 14Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
15. 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2, chapter 6, chapter 8
16. 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
17. 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
18. 18OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
19. 19OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2, chapter 4, chapter 6
20. 20Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X/13 to 16/21; AHTEG; horizon scanning; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03. Cited in chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
21. 21World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing dual-use research (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03. Cited in chapter 4, chapter 6, chapter 8
22. 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8
23. 23BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03. Cited in chapter 1, chapter 3, chapter 4, chapter 6, chapter 8
24. 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03. Cited in the summary, chapter 1, chapter 3, chapter 4, chapter 6, chapter 8
25. 25UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03. Cited in chapter 2, chapter 4, chapter 6, chapter 8
26. 26UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2, chapter 4, chapter 5, chapter 6, chapter 7, chapter 8
27. 27UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03. Cited in chapter 2, chapter 4, chapter 6, chapter 7, chapter 8
28. 28UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2, chapter 6, chapter 8
29. 29UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03. Cited in chapter 2, chapter 6
30. 30UNVERIFIED, not opened: Engineering Biology Research Consortium (ed.), response on nucleic acid synthesis screening under Executive Order 14292, November 2025, listed in search results only. EBRC, Emeryville. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2
31. 31UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03. Cited in chapter 4, chapter 6
32. 32UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03. Cited in chapter 4, chapter 6
33. 33UNVERIFIED, not opened: National Academies of Sciences, Engineering, and Medicine (eds.), Biodefense in the Age of Synthetic Biology, 2018, cited from memory; a fetch returned an unrelated page. National Academies Press, Washington. Observation year 2018. Accessed 2026-11-03. Cited in chapter 6
34. 34UNVERIFIED, not opened: Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction, 1972, cited from memory. United Nations, Geneva. Observation year 1972. Accessed 2026-11-03. Cited in chapter 6
35. 35UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03. Cited in chapter 4, chapter 6, chapter 8
36. 36UNVERIFIED, not opened: International Organization for Standardization (ed.), ISO 20688-2, requirements for the production and quality control of synthesised gene fragments, genes and genome-scale constructs, cited from memory. ISO, Geneva. Observation year 2024. Accessed 2026-11-03. Cited in chapter 6, chapter 8
37. 37UNVERIFIED, not opened: McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020, cited from memory; the fetch returned a service error and no figure is used. McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-03. Cited in chapter 6, chapter 8
38. 38UNVERIFIED, not opened: Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 337, 816 to 821, 2012, cited from memory. Observation year 2012. Accessed 2026-11-03. Cited in chapter 6
39. 39UNVERIFIED, not opened: Gibson, D.G. et al., Enzymatic assembly of DNA molecules up to several hundred kilobases, Nature Methods 6, 343 to 345, 2009, cited from memory. Observation year 2009. Accessed 2026-11-03. Cited in chapter 6
40. 40UNVERIFIED, not opened: Ro, D.-K. et al., Production of the antimalarial drug precursor artemisinic acid in engineered yeast, Nature 440, 940 to 943, 2006, cited from memory. Observation year 2006. Accessed 2026-11-03. Cited in chapter 6
41. 41UNVERIFIED, not opened: Elowitz, M.B. and Leibler, S., A synthetic oscillatory network of transcriptional regulators, Nature 403, 335 to 338, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03. Cited in chapter 6
42. 42UNVERIFIED, not opened: Gardner, T.S., Cantor, C.R. and Collins, J.J., Construction of a genetic toggle switch in Escherichia coli, Nature 403, 339 to 342, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03. Cited in chapter 6
43. 43UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03. Cited in chapter 2, chapter 6, chapter 8
44. 44UNVERIFIED, not opened: bioRxiv preprint of the Syn57 study, Escherichia coli with a 57-codon genetic code, 2025, identified from a search result; the page returned HTTP 429. Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03. Cited in chapter 2

C.2Publication record

Colophon

Format

A4 portrait · screen, print and archival PDF

Typefaces

Space Grotesk (display) · Geist (text) · IBM Plex Sans Italic (standfirsts) · IBM Plex Mono (data)

Design standard

Reports Foundational Edition, Volume I, Part VII

Accessibility

tagged PDF and HTML targets; text alternatives for every figure

Production

Reports editorial team, GCRI

Release path for this version